Emily Mackler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7783081/publications.pdf

Version: 2024-02-01

		933447	1125743	
14	418	10	13	
papers	citations	h-index	g-index	
14	14	14	617	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Prevention and Treatment of Cancer-Related Infections. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1412-1445.	4.9	169
2	Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients. Supportive Care in Cancer, 2011, 19, 1969-1974.	2.2	44
3	2018 Hematology/Oncology Pharmacist Association Best Practices for the Management of Oral Oncolytic Therapy: Pharmacy Practice Standard. Journal of Oncology Practice, 2019, 15, e346-e355.	2.5	35
4	The relationship between patient activation, confidence to self-manage side effects, and adherence to oral oncolytics: a pilot study with Michigan oncology practices. Supportive Care in Cancer, 2017, 25, 1797-1807.	2.2	34
5	Oncology Pharmacist Opportunities: Closing the Gap in Quality Care. Journal of Oncology Practice, 2018, 14, e403-e411.	2.5	29
6	Improving Oral Oncolytic Patient Self-Management. Journal of Oncology Practice, 2016, 12, e864-e869.	2.5	25
7	Evaluation of outpatient medication reconciliation involving student pharmacists at a comprehensive cancer center. Journal of the American Pharmacists Association: JAPhA, 2015, 55, 540-545.	1.5	24
8	Outcomes of therapy vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients. Supportive Care in Cancer, 2012, 20, 1935-1936.	2.2	18
9	Administration of Oral Chemotherapy: Results From Three Rounds of the Quality Oncology Practice Initiative. Journal of Oncology Practice, 2015, 11, e255-e262.	2.5	18
10	Implementing a Method for Evaluating Patient-Reported Outcomes Associated With Oral Oncolytic Therapy. Journal of Oncology Practice, 2017, 13, e395-e400.	2.5	16
11	Clinician Report of Oral Oncolytic Symptoms and Adherence Obtained via a Patient-Reported Outcome Measure (PROM). JCO Clinical Cancer Informatics, 2019, 3, 1-6.	2.1	4
12	Impact of a Statewide Oral Oncolytic Initiative on Five Participating Practices. Journal of Oncology Practice, 2018, 14, e304-e309.	2.5	1
13	Association of high symptom burden with oral oncolytic agents Journal of Clinical Oncology, 2014, 32, 177-177.	1.6	1
14	Medication Adherence Among Adults With Comorbid Chronic Conditions Initiating Oral Anticancer Agent Therapy for Multiple Myeloma. JCO Oncology Practice, 0, , .	2.9	0